Bioverativ

Sanofi Buys Hemophilia Drug Maker for $11B
Strategy

Sanofi Buys Hemophilia Drug Maker for $11B

The acquisition of Bioverativ boosts Sanofi's presence in the fast-growing, $10 billion market for hemophilia treatments.
By Matthew Heller | January 22, 2018
Read More